Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
Completed
Conditions studied: Relapsing-Remitting Multiple Sclerosis
In brief
The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The secondary objective is to further evaluate relapse activity, defined as annualized relapse rate (ARR), hospitalization and intravenous corticosteroid use, during the first year of Tecfidera treatment following transition from Tysabri treatment.
Key facts
- Study ID
- NCT02159573
- Run by
- Biogen
- People needed
- 530
- Starts
- 2014-07-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2016-06-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Birmingham, Alabama, United States
- Research Site — Cullman, Alabama, United States
- Research Site — Gilbert, Arizona, United States
- Research Site — Phoenix, Arizona, United States
- Research Site — Aurora, Colorado, United States
- Research Site — Centennial, Colorado, United States
- Research Site — Washington D.C., District of Columbia, United States
- Research Site — Jacksonville Beach, Florida, United States
- Research Site — Palm Bay, Florida, United States
- Research Site — Tampa, Florida, United States
- Research Site — Athens, Georgia, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Idaho Falls, Idaho, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Peoria, Illinois, United States
- Research Site — Baton Rouge, Louisiana, United States
- Research Site — Glen Burnie, Maryland, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Farmington Hills, Michigan, United States
- Research Site — Golden Valley, Minnesota, United States
- Research Site — Lincoln, Nebraska, United States
- Research Site — Teaneck, New Jersey, United States
- Research Site — Amherst, New York, United States
- Research Site — East Meadow, New York, United States
- Research Site — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.